Sanara MedTech Inc.
SMTI
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $319.3M
$34.73
▲ +0.03%
P/E
-9.34
Mkt Cap
$319.3M
52-Wk Range
$16.05–$35.95
52-Week Range
$16.05 - $35.95
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 2.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary biofilm-disrupting antimicrobial technology with proven efficacy against mature and immature biofilms
- Diversified product portfolio addressing multiple wound types and surgical specialties with differentiated mechanisms of action
- Established distribution network across hospitals, clinics, and post-acute care settings with strong physician relationships
- Patented collagen-based formulations combining healing acceleration with infection prevention
Bear Case
2 risks
- Average volatility.
- Extreme premium - high expectations embedded
Growth
Turning profitable
Expanding prevalence of chronic wounds (diabetic ulcers, pressure ulcers, venous ulcers) driven by aging population and rising diabetes rates
Value
Extreme premium - high expectations embedded
Momentum
Hot
+57.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SMTI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.05 vs -$0.03 consensus (-100.0% surprise). Revenue of $28.1M vs $28.9M expected (-2.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-100.0%
Revenue trend · last 8Q
—
+49%
+26%
+28%
+22%
+5%
+19%
+9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$21.7M
$26.3M
$23.4M
$25.8M
$26.3M
$27.5M
$27.8M
$28.1M
Margins · last 8Q
Gross
95.0%
Operating
6.3%
Profit
-1.6%
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 30, 2026
vs Industry
How SMTI stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related